Is there a role for immunosuppression in antiphospholipid syndrome?
Is there a role for immunosuppression in antiphospholipid syndrome?
Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):426-432
Authors: Sevim E, Willis R, Erkan D
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional APS treatment focuses on antithrombotic strategies, which are usually ineffective for the microvascular and nonthrombotic manifestations of aPL. Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition (eculizumab), mechanistic target of rapamycin inhibition (sirolimus), vascular endothelial cell modulation (defibrotide), statins, and traditional rheumatologic disease-modifying agents (hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide).
PMID: 31808842 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
More News: Antiphospholipid Syndrome | Autoimmune Disease | Cholesterol | Education | Hematology | Hughes Syndrome | Hydroxychloroquine | Pregnancy | Rheumatology | Rituxan | Statin Therapy | Thrombosis | Universities & Medical Training | Velcade